Adagio Therapeutics adds Dr. Redonda Miller and Ellen Marram to its Board of Directors

– USA, MA –  Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced the additions of Dr. Redonda Miller (M.D.) and Ellen Marram to its Board of Directors.

The company also announced the appointment of Jill Andersen as Chief Legal Officer, bringing over 20 years of legal, compliance, and leadership experience in the pharmaceutical industry, government, and private practice.

“The additions of Redonda and Ellen to the Adagio board complement the company’s experienced and seasoned leadership team and board. As the leader of one of the nation’s top hospitals, Redonda provides a valuable patient perspective and key insights into the clinical advancement of compelling medicines, particularly having been on the front lines throughout the COVID-19 pandemic. Ellen brings a unique viewpoint as a proven business leader who has led many organizations and built dozens of profitable consumer brands, many of which address consumer health concerns. We look forward to partnering with them in an effort to deliver much-needed prophylactic and therapeutic options for this ongoing crisis.” said co-Founder and Chairman, Rene Russo.

About Dr. Redonda Miller

Dr. Miller has served as the President of The Johns Hopkins Hospital since 2016 and has advanced the hospital’s focus on providing exceptional clinical care, enhancing quality, safety, and the patient experience, and improving health equity and outcomes for residents in Baltimore City. During her tenure, The Johns Hopkins Hospital has consistently been recognized for extraordinary care, maintaining its rank among the top hospitals in the nation on the U.S. News & World Report Honor Roll and earning its fourth consecutive Magnet designation for nursing excellence. Dr. Miller arrived at Johns Hopkins as a medical student in 1988 and joined the medical faculty in 1997. Since 2004, she has served in several administrative roles of increasing responsibility, including vice-chair of clinical operations for the Department of Medicine, VP of medical affairs for The Johns Hopkins Hospital, and SVP of medical affairs for the Johns Hopkins Health System. In 2020, Dr. Miller was inducted into the National Academy of Medicine and the Maryland Chamber of Commerce Business Hall of Fame.

She holds an M.D. from Johns Hopkins University School of Medicine, an MBA from Johns Hopkins Carey Business School, and a B.S. in biology from The Ohio State University.

About Ellen Marram

Ms. Marram recently retired as the lead director for Eli Lilly and Ford Motor Company and previously served as the presiding director of The New York Times. She was the CEO of the Tropicana Beverage Group and the Nabisco Biscuit Company and, as a managing director or advisor to several private equity firms, primarily focused on health-related consumer brands and served on many private company boards. She is currently the chair of Newman’s Own Inc, the food company which gives all profits to philanthropic causes, and serves as a director of the Newman’s Own Foundation. She also serves on several health-related and other non-profit boards.

Ms. Marram holds an MBA from Harvard Business School and a B.A. from Wellesley College where she serves as a trustee.

About Jill Andersen

Ms. Andersen joins Adagio from Oyster Point Pharma where she served as general counsel, corporate secretary, and chief compliance officer, and recently led and supported critical components of the company’s first FDA approval and product launch. Before that, she was with Bristol Myers Squibb, following the Celgene acquisition, and served as VP, head of legal for the inflammation & immunology global franchise. Before joining Celgene, she held positions of increasing responsibility at Novartis, including senior leadership roles in legal and compliance at Novartis Pharmaceuticals Corporation, Novartis Consumer Health, and Novartis Services. Ms. Andersen has worked extensively on matters related to product development, marketing approval, and commercialization, including product launches across multiple therapeutic areas. Her experience also spans corporate governance, securities, corporate transactions, IP, litigation, and investigations. Before joining the pharmaceutical industry, she was an Assistant U.S. Attorney for the District of New Jersey and was a litigation associate at the law firm of Davis Polk & Wardwell.

She holds a J.D. from Wake Forest University, School of Law, and a B.S. in finance from Boston College.

About Adagio Therapeutics

Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability, and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launches, ensuring the potential for broad access to people around the world.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team